Program
oveporexton
Also written as “TAK-861”, “Oveporexton” and “TAK-861 2 mg”.
Its studies are mostly in Narcolepsy, led by Takeda.
Furthest: phase 3, since Mar 31, 20236 company-led studies, 2 open or runningNext primary completion: Dec 17, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 62 open or running | phase 3since Mar 31, 2023 | Jan 9, 2023 | Dec 17, 2026phase 3 · NCT07363720 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2023First studies: 2 phase 2 studiesFirst studyNCT05687916, NCT05687903
- Mar 31, 2023Phase 3 study in Narcolepsy Type 1NCT05816382 · 500 planned · United States, Australia, Finland and more
- Jun 18, 2024Phase 3 study in Narcolepsy Type 1NCT06470828 · 168 enrolled · United States, Canada, France and more
- Jul 11, 2024Phase 3 study in Narcolepsy Type 1NCT06505031 · 105 enrolled · Australia, Austria, Belgium and more
- Jan 7, 2026Phase 3 study in NarcolepsyNCT07363720 · 98 enrolled · United States, France, Germany and more
- Oct 30, 2026Primary completion moved from 2026-10-02 to 2026-12-17Date moved laterphase 3 · +2 months · NCT07363720
Ahead
- Dec 17, 2026Primary completion: phase 3 study in NarcolepsyNCT07363720
- Feb 28, 2028Primary completion: phase 3 study in Narcolepsy Type 1NCT05816382
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07363720Narcolepsy · United States, France, Germany and more | 3 | Active, not recruiting | Dec 17, 2026 | 98 |
| NCT06505031Narcolepsy Type 1 · Australia, Austria, Belgium and more | 3 | Completed | Jun 4, 2025 | 105 |
| NCT06470828Narcolepsy Type 1 · United States, Canada, France and more | 3 | Completed | Jun 3, 2025 | 168 |
| NCT05816382Narcolepsy Type 1 · United States, Australia, Finland and more | 3 | Recruiting | Feb 28, 2028 | 500 |
| NCT05687916Narcolepsy Type 2 · United States, Australia, Finland and more | 2 | Completed | Dec 13, 2023 | 71 |
| NCT05687903Narcolepsy Type 1 · United States, Australia, Finland and more | 2 | Completed | Dec 14, 2023 | 112 |
How it is read
Names in the registry
- “TAK-861”, 4 entries
- “Oveporexton”, 1 entry
- “TAK-861 2 mg”, 1 entry
- “TAK-861 2 mg and 5 mg”, 1 entry
Conditions, from the studies’ own filings
- Narcolepsy, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.